The Medical Developments International Ltd (ASX: MVP) share price is drifting deep into the red in early trade on Monday.
At the time of writing, the share trades 17% lower at $1.99 following the release of a company announcement.
What did Medical Developments announce?
The company advised it has successfully completed the institutional components of its planned fully-underwritten $30 million capital raising.
The 1 for 9.5 pro-rata entitlement offer raised $5 million in tranches of an institutional placement and entitlement offer. The company reported good support from existing shareholders.
Meanwhile, the underwritten placement raised approximately $15 million, with a total of 7.5 million new shares issued.
Medical Developments announced the funding round last week. It plans to put the funds towards the company’s expansion into Europe, the Australian ambulance sector, and investment directly into the business.
It now intends to raise a further $10 million through a retail entitlement offer. The offer will open on 11 August and run until 25 August 2022.
Speaking on the announcement, Medical Developments chair Gordon Naylor said:
I would like to thank our shareholders for their support and welcome our new investors onto the MVP share register. Their strong funding support will enable our investment to continue executing on our European and Australian growth strategies.
Further developments will likely be released closer to 25 August when the retail entitlement offer is set to close.
In the last 12 months, the Medical Developments share price is down more than 52%, and 60% this year to date.
The post Here’s why the Medical Developments share price is sinking 17% on Monday appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of July 7 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/5MrTR7C
Leave a Reply